Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

MHRA

Drug and asset intelligence for MHRA with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Stage
Development stage unavailable

Recent signals(8)

RegulatoryJuly 25, 2026

MHRA Issues Guidance on Safe Use of GLP-1 Weight Loss Medicines

The MHRA emphasizes the importance of safe usage of GLP-1 medicines amid rising demand for weight-loss solutions.

RegulatoryJuly 22, 2026

MHRA Approves First Lower-Carbon Beclometasone Inhalers for Asthma

The MHRA has approved the world's first lower-carbon beclometasone inhalers, utilizing a next-generation propellant.

RegulatoryJuly 16, 2026

MHRA Strengthens Warnings for Botulinum Toxin Type A Products Due to Botulism Cases

The MHRA has issued updated safety warnings for botulinum toxin type A products due to rare cases of botulism.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Asthma →
Bladder Cancer →
Obesity →
Rare Diseases →

Therapeutic areas

AI in Drug Development →
Asthma →
Bladder Cancer →
Botulinum Toxin →
General →
GLP-1 →
Hematology →
Neurology →
Obesity →
Oncology →
Plasma-derived Products →
Plasma-derived therapies →
Rare Diseases →
Respiratory →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

RegulatoryJuly 10, 2026

MHRA Reviews Safety of Five Plasma-Derived Products for vCJD Risk

The MHRA has completed a review of five plasma-derived medicinal products regarding their safety related to vCJD risk.

RegulatoryJuly 10, 2026

MHRA Approves UK Plasma Donations for Key Medicinal Products

The MHRA has approved the use of UK-donor plasma for five high-priority plasma-derived medicinal products.

RegulatoryJuly 9, 2026

MHRA Launches Consultation for Earlier Licensing of Rare Disease Therapies

The MHRA has initiated a public consultation on a new framework aimed at expediting the licensing process for therapies targeting rare diseases.

RegulatoryJuly 2, 2026

MHRA Approves Gemcitabine Delivery System for High-Risk Bladder Cancer

The MHRA has authorized a new intravesical delivery system for gemcitabine aimed at adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer.

RegulatoryJune 22, 2026

MHRA Launches AI Sandbox to Enhance Medicines Development and Safety

The MHRA has launched an AI sandbox aimed at accelerating the development of medicines and improving safety.

Various →